Resistance to targeted cancer drugs through hepatocyte growth factor signaling.
Cell Cycle
; 13(24): 3808-17, 2014.
Article
em En
| MEDLINE
| ID: mdl-25426675
ABSTRACT
Cancer therapeutics that target a signaling pathway to which the cancer cells are addicted can deliver dramatic initial responses, but resistance is nearly always inevitable. A variety of mechanisms that cancer cells employ to escape from targeted cancer drugs have been described. We review here the role of Hepatocyte Growth Factor (HGF) and its receptor MET in drug resistance. We present data demonstrating that HGF can confer resistance to a number of kinase inhibitors in a variety of cancer cell lines and discuss our results in relation to the findings of others. Together, these data point at a major role for HGF/MET signaling in resistance to a variety of targeted cancer drugs.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Transdução de Sinais
/
Fator de Crescimento de Hepatócito
/
Proteínas Proto-Oncogênicas c-met
Limite:
Humans
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article